2024/12/05 by Anthony M. Marchese, Hadi Beyhaghi, Matthew D. Rousculp +4 · 2 voices
Medicine · Social Sciences · Immunology and Microbiology · #SARS-CoV-2 and COVID-19 Research #Vaccine Coverage and Hesitancy #Bacterial Infections and Vaccines
paper · doi:10.1016/j.vaccine.2024.126569
Reactogenicity, the occurrence of vaccine side effects, can impact vaccine acceptance. There is limited data comparing the reactogenicity of COVID-19 vaccines to other routinely used vaccines, such as the meningococcal conjugate vaccine (MenACWY). In a trial of UK adults, participants received a third COVID-19 vaccine dose (NVX-CoV2373, BNT162b2, or mRNA1273) alongside MenACWY as an active control. Compared to MenACWY, we found that mRNA vaccines, particularly mRNA1273, showed the greatest relative increase in side effects, while protein-based NVX-CoV2373 generally elicited similar reactogenicity to MenACWY. These findings suggest that platform type can influence vaccine reactogenicity, and further research is needed to compare COVID-19 vaccines with other routinely administered vaccines. • Vaccine platform type can influence the occurrence of reactogenic events. • Evidence comparing reactogenicity of COVID vaccines to other vaccines is limited. • Compared to MenACWY, mRNA COVID vaccines showed higher reactogenicity. • Protein-based COVID vaccine NVX-CoV2373 elicited similar reactogenicity to MenACWY. • Further research is needed to compare COVID and other routinely administered vaccines.